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year was considered. Base case model outputs were total cost, cost per member 
per month (PMPM) and number of UP. RESULTS: In a hypothetical cohort of 1 
million plan members, the model estimated reductions of $460,552USD in total 
costs, $0.03USD in PMPM costs, and 119 in UP. CONCLUSIONS: Switching SARC 
method users to LNG-IUS-12 in a US health care plan may result in fewer UP and 
an overall cost savings to the plan.  
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OBJECTIVES: Stress urinary incontinence (SUI) is associated with a hefty 
economic burden. Mid-urethral slings have become common surgical options for 
women with SUI. This study examines the costs of transobturator slings for SUI 
surgeries. METHODS: A model was created to estimate the budget impact to 
hospitals of transobturator sling surgery in women with SUI. Current practice 
using transobturator slings including the Monarc™ Subfascial Hammock, 
Obtryx® Transobturator Mid-Urethral Sling System, Aris® Transobturator Sling 
System, Align® TO Trans-Obturator Urethral Support System, Desara® Sling 
System, Gynecare TVT™ Obturator System Tension-free Support for 
Incontinence and Gynecare TVT Abbrevo™ Continence System were modeled. 
Four surgical complications were also considered: re-operation due to failure, 
revision or removal of sling, urologic complications including urinary obstruction 
and urinary tract infection, and pelvic complications. This model calculates the 
average one-year cost per patient with the use of each sling product and predicts 
the total budget for sling urinary incontinence surgery associated with each 
product based on these estimates. RESULTS: Average combined cost of the sling 
and for management of complications over one year ranged from $2,666 
(Gynecare TVT™ Obturator) to $3,213 (Desara®) per patient. With the current 
market share for transobturator sling products, the expected expenditure is 
around $293,669 for a hypothetical surgical population of 100 patients. Sling 
costs account for approximately $105,526 (36%) of this cost with complications 
making up the remainder. While cost of Gynecare slings are not the least, 
increase in the share of use of these slings resulted in lowering of overall 
expenditure. CONCLUSIONS: This study represents the first comparative 
assessment of the costs of different sling options for SUI surgeries. Gynecare 
transobturator slings represent a sound economic choice for hospitals with an 
expected reduction in overall expenditure compared with others. Moreover, such 
reduction is obtained at the benefit of patients who experience fewer 
complications.  
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OBJECTIVES: To estimate the budget impact analysis of replacing Tobramycin 
Inhalation Solution (TIS) by TIP in the public health care system. METHODS: A 
financial cash flow of treatment, concomitant treatment (ciprofloxacin) was 
estimated using TIP instead of TIS in the 315 patients currently identified 
receiving treatment. Efficacy is the same between the two presentations 
(Konstan, 2011); adverse events do not represent additional costs. However the 
time needed to nebulization treatment, and device cleaning is longer with TIS: 28 
and 33 minutes more per day, respectively. Therefore a societal impact is 
estimated using the societal time value for economic evaluations of US$2.64 
hour. (ER 1US$=13MX$). RESULTS: The cycle cost per patient of TIS=US$2269.23 
and TIP=US$2155.76. The annual 6-cycles cost is US$13,617.81 for TIS and 
US$12,937.21 for TIP. Savings account for US$680.52 per patient (5%). The Health 
System could be saving US$214,442.30. The difference in the hours invested to 
drug administration between TIS and TIP is 78.4 hours-year, and the difference 
for cleaning the device is 92.4 hours-year, less for TIP in both cases. 
Economically, it represents an incremental societal investment of using TIS of 
$1798 per patient a year. CONCLUSIONS: The time burden to receive treatment 
in CF is huge. Patients spend around 2 hours a day. TIP represents an 
opportunity for saving both health care resources, and valuable time to patients, 
and caregivers.  
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OBJECTIVES: Health economic analyses have shown that providing free 
contraceptive cover leads to cost savings of 15–17% when considering the cost of 
managing unintended pregnancies and their outcomes. The US Patient 
Protection and Affordable Care Act (PPACA) mandates employers to include 
contraceptives in their employees’ health care coverage at no out-of-pocket cost 
to women. This model estimates the budget impact and cost-effectiveness to the 
US health care system of providing this coverage to women across different 
employment and insurance settings. METHODS: An age-specific Markov model 
was developed for women aged 15–44, using data from the US Census Bureau 
and National Survey of Family Growth. The model explored direct medical costs 
associated with contraceptive coverage. The direct medical costs of unintended 
pregnancy (live birth, abortion, miscarriage and ectopic pregnancy) were sourced 
from published literature identified using Pubmed. The model considered the 
impact of altered contraceptive use associated with free coverage (using data 
from the CHOICE study), and accounted for differences in efficacy between these 
modalities. RESULTS: The model showed that savings may be realised by the US 
health care system when contraceptives are provided free of charge to women at 
risk of unintended pregnancy, a strategy which remained cost-effective over a 
variety of sensitivity analyses. Key drivers of savings included the tenfold 
increase in recourse to long-acting reversible contraceptive methods, which led 
to a three- and five-fold decrease in unintended pregnancies and associated 
medical costs, respectively. CONCLUSIONS: This model is the first to estimate 
the impact, to the US health care system, of the PPACA mandate for free 
contraception, accounting for revised contraceptive usage when coverage is 
provided with no out-of-pocket costs. Findings suggest that providing 
contraception free of charge is cost-effective and cost-saving for the US health 
care system, and could be even more so were indirect and intangible costs 
considered.  
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OBJECTIVES: Rotavirus (RV) is the leading cause of severe gastroenteritis in 
infants and young children worldwide. We aimed to assess the cost-
effectiveness of two different RV vaccines in Mexico. METHODS: The analysis 
was conducted by calibrating a previously published deterministic Markov model 
with existing national data. Competing alternatives included routine 
immunization with a two-dose (2d: first/second dose at 2/4 months of age) or a 
three-dose (3d: first/second/third dose at 2/4/6 months of age) schemes besides 
the non-vaccination strategy. The model simulated the vaccines effect at vaccine 
steady-state condition over a period of 5 years under the perspective of Mexican 
public health care system. Direct medical costs comprising both acquisition and 
administration of RV vaccines as well as treatment of emerging RV infections 
were assessed. Costs are expressed in 2012 Mexican pesos (MXN). It was 
assumed that once completed, both vaccines are equally effective. Therefore, 
compliance and efficacy per each dose were incorporated into the analysis. 
Utility scores were obtained from literature. A 5% annual discount rate was 
applied. RESULTS: Without vaccination 760,559 cumulative RV events are 
expected for the 2012 birth cohort, entailing direct medical costs of 529.3 million 
MXN and a loss of 5,036 quality-adjusted life years (QALY). The two-dose scheme 
reduced RV events (39%), frequency of cases seeking medical advice (58%)  
and hospital admissions due to RV (67%). For 3d, these reductions were 30%, 45% 
and 53%, respectively. When compared to non-vaccination, the costs per 
additional QALY gained were $26,408 MXN (2d) and $69,325 MXN (3d). 2d  
was associated with net savings of 74 million MXN (11%) plus a gain of 553 QALY 
with respect to 3d. Sensitivity analysis showed model is robust. CONCLUSIONS: 
These results suggest routine immunization against RV with either 2d or 3d is a 
highly cost-effective intervention in Mexico. Among the vaccines, 2d was 
dominant.  
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OBJECTIVES: To describe the costs and clinical outcomes of global endometrial 
ablation (GEA) and hysterectomy for the treatment of menorrhagia among 
women insured through Medicaid programs. METHODS: The Truven Health 
MarketScan® Medicaid Multi-State Database was used to identify Medicaid 
recipients aged 30-55 years with diagnosed menorrhagia who initiated treatment 
for menorrhagia with GEA or hysterectomy during 2006-2010. Patients were 
required to have 12 months of continuous enrollment pre- and post-treatment 
initiation (index event). Baseline characteristics were assessed in the year prior 
to treatment initiation. Health care utilization and costs (2011 USD) were 
assessed in the year following treatment initiation. RESULTS: A total of 1880 
women met the study criteria (mean age=40.7); approximately one-half (53.4%) 
were Caucasian, 33.1% were African-American, and 2.3% were Hispanic. Nearly 
one-half (42.8%) of the women received their Medicaid eligibility due to 
disability. Slightly more patients received GEA (50.9%) than hysterectomy (49.1%). 
Both GEA and hysterectomy patients had similar baseline Deyo-Charlson 
Comorbidity scores (0.65) and similar baseline use of anti-biotics (69.4%), non-
steroidal anti-inflammatory drugs (56.3%), or oral contraceptives (5.3%). More 
than one-half (52%) of hysterectomy patients had a treatment-related 
complication, compared to 36% of GEA patients (p<0.0001). Index treatment costs 
plus 30-day follow-up costs were higher for hysterectomy ($11,270) than for GEA 
($3,958, p<0.0001). Gynecologic-related costs in the remainder of the year were 
$694 for hysterectomy and $175 for GEA (p=0.14). Nearly all GEA (93%) procedures 
occurred in an outpatient setting while 87% of hysterectomies occurred in an 
inpatient setting. CONCLUSIONS: Hysterectomy and related post-operative costs 
were nearly 3 times higher than GEA costs for the treatment of menorrhagia. 
These results and others from this study are timely, as new federal mandates for 
Medicaid expansion are likely to focus on outpatient treatments as ways to 
reduce Medicaid costs.  
